Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16361554rdf:typepubmed:Citationlld:pubmed
pubmed-article:16361554lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:16361554lifeskim:mentionsumls-concept:C0249582lld:lifeskim
pubmed-article:16361554lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:16361554lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:16361554lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:16361554pubmed:issue24 Pt 1lld:pubmed
pubmed-article:16361554pubmed:dateCreated2005-12-19lld:pubmed
pubmed-article:16361554pubmed:abstractTextWe assessed the safety and efficacy of the vitamin D analogue, 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol), in patients with androgen-independent prostate cancer.lld:pubmed
pubmed-article:16361554pubmed:languageenglld:pubmed
pubmed-article:16361554pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:citationSubsetIMlld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16361554pubmed:statusMEDLINElld:pubmed
pubmed-article:16361554pubmed:monthDeclld:pubmed
pubmed-article:16361554pubmed:issn1078-0432lld:pubmed
pubmed-article:16361554pubmed:authorpubmed-author:TortiFrank...lld:pubmed
pubmed-article:16361554pubmed:authorpubmed-author:SchwartzGary...lld:pubmed
pubmed-article:16361554pubmed:authorpubmed-author:HallM CraigMClld:pubmed
pubmed-article:16361554pubmed:authorpubmed-author:PattonSuzanne...lld:pubmed
pubmed-article:16361554pubmed:authorpubmed-author:LovatoJamesJlld:pubmed
pubmed-article:16361554pubmed:authorpubmed-author:StindtDianaDlld:pubmed
pubmed-article:16361554pubmed:issnTypePrintlld:pubmed
pubmed-article:16361554pubmed:day15lld:pubmed
pubmed-article:16361554pubmed:volume11lld:pubmed
pubmed-article:16361554pubmed:ownerNLMlld:pubmed
pubmed-article:16361554pubmed:authorsCompleteYlld:pubmed
pubmed-article:16361554pubmed:pagination8680-5lld:pubmed
pubmed-article:16361554pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:meshHeadingpubmed-meshheading:16361554...lld:pubmed
pubmed-article:16361554pubmed:year2005lld:pubmed
pubmed-article:16361554pubmed:articleTitlePhase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer.lld:pubmed
pubmed-article:16361554pubmed:affiliationDepartment of Cancer Biology, Wake Forest University, Winston-Salem, NC 27157, and Nortwest Georgia Oncology Centers, Douglasville, USA.lld:pubmed
pubmed-article:16361554pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16361554pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16361554pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:16361554pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16361554lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16361554lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16361554lld:pubmed